Cambridge biotech startup grabs $65M to tackle liver disease
June 25, 2018 at 07:00 AM EDT
The company, Akero Therapeutics, is focused on a type of liver disease called NASH that affects an estimated 16 million Americans.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|